Teresa K. Tarrant

Dr. Teresa K. Tarrant

Medicine, Duke University Hospital, Durham, California, USA
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2021 in Nature Reviews Chemistry
Verified
Journal Article
Closed access
PDF file
BVBrianna M. Vickerman
Brianna M. Vickerman
EZEmilia M. Zywot
Emilia M. Zywot
TTTeresa K. Tarrant
Teresa K. Tarrant
DLDavid Lawrence
David Lawrence

18 June 2021 in Science
Verified
Journal Article
Closed access
PDF file
KKKorbinian Kienle
Korbinian Kienle
KGKatharina M. Glaser
Katharina M. Glaser
SESarah Eickhoff
Sarah Eickhoff
MMMichael Mihlan
Michael Mihlan
KKKonrad Knöpper
Konrad Knöpper
TLTim Lämmermann
Tim Lämmermann
Stopping the swarm: Neutrophils play a major role in the early immune response and are recruited in large numbers into inflamed and infected tissues. By secreting chemoattractants that bind G protein–coupled receptors (GPCRs) on neighboring cells, neutrophils coordinate their behavior as a swarm. Less clear is how this auto-amplifying swarming activity is ultimately turned off. Kienle et al. show that desensitization of these GPCRs by the same chemoattractants by GPCR-kinase 2 (GRK2) is one way in which these swarms are shut down (see the Perspective by Rocha-Gregg and Huttenlocher). Unexpectedly, mice with GRK2-deficient neutrophils showed impaired rather than enhanced bacterial clearance. The heightened scanning ability of GRK2-deficient neutrophils may come at the cost of suboptimal phagocytosis and containment of bacteria. Science , abe7729, this issue p. eabe7729 ; see also abj3065, p. 1262

3 August 2014 in Current Allergy and Asthma Reports
Verified
Journal Article
Closed access
PDF file
SSShaili Shah
Shaili Shah
EWEveline Wu
Eveline Wu
VRV. Koneti Rao
V. Koneti Rao
TTTeresa K. Tarrant
Teresa K. Tarrant

2 July 2019 in Current Allergy and Asthma Reports
Verified
Journal Article
Closed access
PDF file
VWVictoria A. Wickenheisser
Victoria A. Wickenheisser
EZEmilia Marta Zywot
Emilia Marta Zywot
EREmily Mary Rabjohns
Emily Mary Rabjohns
HLHyun Ho Lee
Hyun Ho Lee
DLDavid S. Lawrence
David S. Lawrence
TTTeresa K. Tarrant
Teresa K. Tarrant

4 July 2024 in Blood
Verified
Journal Article
Open access
PDF file
RBRaffaele Badolato
Raffaele Badolato
LALaia Alsina
Laia Alsina
AAAntoine Azar
Antoine Azar
YBYves Bertrand
Yves Bertrand
ABAudrey A. Bolyard
Audrey A. Bolyard
JDJean Donadieu
Jean Donadieu
We investigated efficacy and safety of mavorixafor, an oral CXCR4 antagonist, in participants with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a rare immunodeficiency caused by CXCR4 gain-of-function variants. This randomized (1:1), double-blind, placebo-controlled, phase 3 trial enrolled participants aged ≥12 years with WHIM syndrome and absolute neutrophil count (ANC) ≤0.4 × 103/μL. Participants received once-daily mavorixafor or placebo for 52 weeks. The primary end point was time (hours) above ANC threshold ≥0.5 × 103/μL (TATANC; over 24 hours). Secondary end points included TAT absolute lymphocyte count ≥1.0 × 103/μL (TATALC; over 24 hours); absolute changes in white blood cell (WBC), ANC, and absolute lymphocyte count (ALC) from baseline; annualized infection rate; infection duration; and total infection score (combined infection number/severity). In 31 participants (mavorixafor, n = 14; placebo, n = 17), mavorixafor least squares (LS) mean TATANC was 15.0 hours and 2.8 hours for placebo (P < .001). Mavorixafor LS mean TATALC was 15.8 hours and 4.6 hours for placebo (P < .001). Annualized infection rates were 60% lower with mavorixafor vs placebo (LS mean 1.7 vs 4.2; nominal P = .007), and total infection scores were 40% lower (7.4 [95% confidence interval [CI], 1.6-13.2] vs 12.3 [95% CI, 7.2-17.3]). Treatment with mavorixafor reduced infection frequency, severity, duration, and antibiotic use. No discontinuations occurred due to treatment-emergent adverse events (TEAEs); no related serious TEAEs were observed. Overall, mavorixafor treatment demonstrated significant increases in LS mean TATANC and TATALC, reduced infection frequency, severity/duration, and was well tolerated. The trial was registered at www.clinicaltrials.gov as #NCT03995108.

9 November 2020 in Stem Cells
Verified
Journal Article
Closed access
HMHyunjung Min
Hyunjung Min
LXLi Xu
Li Xu
RPRoberta Parrott
Roberta Parrott
COChristopher C. Overall
Christopher C. Overall
MLMelina Lillich
Melina Lillich
AFAnthony J. Filiano
Anthony J. Filiano